Drug intelligence / Profile preview

gemcitabine + cisplatin + oxaliplatin + durvalumab + pembrolizumab + sintilimab + toripalimab

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A complex combination therapy consisting of three chemotherapy agents (gemcitabine, cisplatin, oxaliplatin) and four immune checkpoint inhibitors (durvalumab, pembrolizumab, sintilimab, toripalimab). Individual components have established roles in cancer treatment, but this specific seven-drug combination is not standard practice and lacks documentation in clinical literature.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)DNARNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on gemcitabine + cisplatin + oxaliplatin + durvalumab + pembrolizumab + sintilimab + toripalimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + cisplatin + oxaliplatin + durvalumab + pembrolizumab + sintilimab + toripalimab.

Explore the full profile